Ads
related to: pfizer breast cancer drug- Understand Your Diagnosis
See How A Metastatic Breast
Breast Cancer Treatment Works.
- Get MBC Treatment Info
Connect With A Rep Or Register For
Updates For A Treatment Option.
- MBC Treatment Option
Visit
Patient Site
- Safety Info & Study Data
View Potential Side Effects Of A
Metastatic Breast Cancer Drug.
- Understand Your Diagnosis
Search results
Sana Al Sukhun, MD, on Metastatic Breast Cancer Treatment in Lower-Income Settings
MedPage Today· 3 days agoTreatment guidelines for patients with metastatic breast cancer often recommend tests, drugs, and...
Pfizer sees lung cancer drug topping $1 billion in sales following impressive 5-year data
FOX Business· 7 days agoPfizer said it expects its cancer drug Lorbrena to top $1 billion in annual sales by 2030 on the...
Antibody-Drug Conjugate Picks Up Another Win in HR+/HER2-low Breast Cancer
MedPage Today· 6 days agoThe antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) significantly improved...
About 20% of Breast Cancer Survivors Gain Excess Weight
Medscape· 16 hours agoYounger age and lower weight at diagnosis strongly predicted at least a 10% weight gain in patients.
Relay Therapeutics to Collaborate with Pfizer to Evaluate Breast Cancer Treatment
Market Watch· 2 days agoRelay Therapeutics will collaborate with Pfizer to study atirmociclib in combination with RLY-2608 and fulvestrant in patients with certain types of metastatic breast ...
ASCO 2024: What's New in Breast Cancer Research?
Medscape· 2 days agoDrs Alexandra Thomas and Virginia Kaklamani discuss highlights in breast cancer research from the ASCO 2024 Annual Meeting.
Cancer Drugs: Deals and Licensing for Antibody-Drug Conjugates
The National Law Review· 2 days agoAntibody-drug conjugates (ADCs) are a promising class of cancer treatments with an accelerating...
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Zacks· 16 hours agoData from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.
ASCO24: Can Ambrx’s novel ADC break into the metastatic breast cancer market?
Pharmaceutical Technology via Yahoo Finance· 4 days agoThe...European approval will not be possible. At the time ACE-Breast-02 started, a head-to-head...
Dublin biotech relocates HQ to Boston - Boston Business Journal
The Business Journals· 2 days agoCarrick Therapeutics Inc. is shipping up to Boston. The clinical-stage cancer company has been based...